Literature DB >> 23887007

Forging stronger partnerships between academic health centers and patient-driven organizations.

Elaine K Gallin1, Enriqueta Bond, Robert M Califf, William F Crowley, Pamela Davis, Richard Galbraith, E Albert Reece.   

Abstract

In this article, the authors review the unique role that patient-driven organizations, such as patient advocacy groups and voluntary health organizations (PAG/VHOs), play in translational and clinical research. The importance of fostering collaborations between these organizations and U.S. academic health centers (AHCs) is also discussed. Although both the PAG/VHO community and AHCs are heterogeneous, and although not all organizations are well governed or provide independent, well-researched views, there are many outstanding, well-managed, independent PAG/VHOs in the United States whose missions overlap with those of AHCs. The characteristics of effective PAG/VHOs that would serve as excellent partners for AHCs are discussed, and examples are provided regarding their many contributions, which have included advancing research on rare diseases, recruiting patients for clinical trials, and establishing patient registries and biospecimen banks. The authors present feedback obtained from informal discussions with PAG/VHO staff, as well as a survey of a small sample of organizations, that has identified bureaucratic processes, negotiating intellectual property rights, and institutional review board (IRB) delays as the most problematic areas of interactions with AHCs. Actions are suggested for building effective partnerships between the two sectors and the activities that AHCs should undertake to facilitate their interactions with PAG/VHOs including streamlining contract review and IRB processes and finding ways to better align the incentives motivating academic clinical and translational investigators with the goals of PAG/VHOs. This article is one product of the Clinical Research Forum's Partnering with Patient Advocacy Groups Initiative.

Entities:  

Mesh:

Year:  2013        PMID: 23887007     DOI: 10.1097/ACM.0b013e31829ed2a7

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  8 in total

1.  Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.

Authors:  Kelly A Edwards; Sharon F Terry; Dana Gold; Elizabeth J Horn; Mary Schwartz; Molly Stuart; Suzanne D Vernon
Journal:  Biopreserv Biobank       Date:  2016-04-08       Impact factor: 2.300

2.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

Review 3.  From promising molecules to orphan drugs: Early clinical drug development.

Authors:  Marc Dooms
Journal:  Intractable Rare Dis Res       Date:  2017-02

4.  Pediatric nephrologists' beliefs regarding randomized controlled trials.

Authors:  Aaron G Wightman; Assaf P Oron; Jordan M Symons; Joseph T Flynn
Journal:  J Investig Med       Date:  2014-01       Impact factor: 2.895

5.  Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey.

Authors:  Sophia K Smith; Wendy Selig; Matthew Harker; Jamie N Roberts; Sharon Hesterlee; David Leventhal; Richard Klein; Bray Patrick-Lake; Amy P Abernethy
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

6.  Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Authors:  William T Cefalu; Sanjay Kaul; Hertzel C Gerstein; Rury R Holman; Bernard Zinman; Jay S Skyler; Jennifer B Green; John B Buse; Silvio E Inzucchi; Lawrence A Leiter; Itamar Raz; Julio Rosenstock; Matthew C Riddle
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

7.  Culture and Process Change as a Priority for Patient Engagement in Medicines Development.

Authors:  Marc Boutin; Lode Dewulf; Anton Hoos; Jan Geissler; Veronica Todaro; Roslyn F Schneider; Vincenzo Garzya; Andrew Garvey; Paul Robinson; Tonya Saffer; Sarah Krug; Ify Sargeant
Journal:  Ther Innov Regul Sci       Date:  2016-08-20       Impact factor: 1.778

8.  The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network.

Authors:  Peter A Merkel; Michele Manion; Rashmi Gopal-Srivastava; Stephen Groft; H A Jinnah; David Robertson; Jeffrey P Krischer
Journal:  Orphanet J Rare Dis       Date:  2016-05-18       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.